Navigation Links
Trovagene Announces Closing of Private Placement of $3.76 Million from the Sale of Restricted Common Stock and Warrants
Date:11/21/2012

SAN DIEGO, Nov. 21, 2012 /PRNewswire/ -- Trovagene, Inc.  (NASDAQ: TROV), a transrenal molecular diagnostic company, today announced the closing of a private placement consisting of 940,000 units at a purchase price of $4.00 per unit, with each unit consisting of one share of unregistered common stock and one warrant to purchase one share of common stock. The gross proceeds to Trovagene from this offering are approximately $3.76 million. The warrants are exercisable for five years from the date of closing at an exercise price of $5.32 per share.

(Logo: http://photos.prnewswire.com/prnh/20120620/LA28014LOGO)

Trovagene intends to use the net proceeds from this private placement offering to fund its research and development activities, and for working capital and other general corporate purposes.

"This private placement is well timed to provide Trovagene with sufficient capital to facilitate the availability of transrenal oncogene mutation testing to clinicians through our diagnostic laboratory," stated Antonius Schuh, Ph.D., chief executive officer of Trovagene.  "The Company now has cash in excess of $10 million, which we expect will be sufficient to fund our operations well into 2014."

This announcement is neither an offer to sell nor a solicitation of an offer to buy any securities of the Company. The securities offered and sold in the private placement have not been registered under the Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States absent registration, or an applicable exemption from registration under the Securities Act and applicable state securities laws.

About Trovagene, Inc.

Headquartered in San Diego, California, Trovagene is developing its patented technology for the detection of transrenal DNA and RNA, short nucleic acid fragments, originating from normal and diseased cell death that cross the kidney barrier and can be detected in urine. Trovagene has a strong patent position as it relates to transrenal molecular testing. It has U.S. and European patent applications and issued patents that cover testing for HPV and other infectious diseases, cancer, transplantation, prenatal and genetic testing. In addition, it owns worldwide rights to nucleophosmin-1 (NPM1), an informative biomarker for acute myeloid leukemia (AML) and mutations in the SF3B1 gene, which have been shown to be associated with chemotherapy response in chronic lymphocytic leukemia (CLL) patients.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on Trovagene's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any medical diagnostic tests under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. Trovagene does not undertake an obligation to update or revise any forward-looking statement.  Investors should read the risk factors set forth in Trovagene's Form 10-K for the year ended December 31, 2011 and other periodic reports filed with the Securities and Exchange Commission.Contact Trovagene, Inc. Financial

Investor RelationsStephen Zaniboni

Amy CaterinaChief Financial Officer

Investor RelationsTrovagene, Inc.

Trovagene, Inc.858-952-7594

858-952-7593szaniboni@trovagene.com 

acaterina@trovagene.com


'/>"/>
SOURCE Trovagene, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Dr. Paul Billings joins Trovagenes Scientific Advisory Board
2. Trovagene, Inc., Announces Third Quarter and Year to Date Earnings, Provides Milestone Update
3. Trovagene and Strand Life Sciences Agree to Validate and Commercialize Urine-Based HPV Test in India and South Asia
4. Trovagene, Inc. Announces Second Quarter and Year to Date Earnings, Provides Milestone Update
5. Trovagene, Inc., Announces Issuance of U.S. Patent for NPM Mutants to Diagnose and Monitor Acute Myeloid Leukemia
6. Trovagene to Study Trans-Renal KRAS Mutation Detection in Pancreatic Cancer
7. Trovagene Announces Plans to Develop Proprietary Test for High Risk HPV Carrier Screening from Urine
8. Keith McCormick Joins Trovagene, Inc. as Head of Commercial Operations
9. ResMed Inc. Announces Exchange Rate For Upcoming Dividend Payment
10. AspenBio Pharma Announces Closing of Public Offering of 1,946,000 Shares of Common Stock
11. Vasomedical Announces Financial Results for the Third Quarter of 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ISELIN, New Jersey , April 29, 2016 ... Omnichannel Software Suite for Life Sciences, Product Development ... and Global Life Science Customer Base . ... healthcare solutions provider, today announced the acquisition of ... is a global leader in adaptive sales enablement ...
(Date:4/29/2016)... Automation is one of the ... the growing demands for productivity in speed, accuracy, throughput ... are already adept of a wide range of functions ... labor. Instrumentation continues to evolve, and is poised to ... few years ago. Originally used mostly by the big ...
(Date:4/28/2016)... -- Research and Markets has announced the ... 2016-2020" report to their offering.      ... global plastic surgery products market is expected to grow ... , ,The growing adoption of laser in aesthetics is ... market. Lasers are used to treat a broad range ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... ... infants born with severe congenital diaphragmatic hernia have better survival rates if surgery ... diaphragmatic hernia (CDH)—a condition where the diaphragm fails to form completely, letting abdominal ...
(Date:4/29/2016)... , ... April 29, 2016 , ... Mobility Designed ... put pressure on the armpits, the M+D Crutch evenly distributes body weight from the ... wrists and hands when using the crutches than with other crutches. , Co-founders Max ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... Melanoma is the deadliest type of skin ... blame for the majority of skin cancer deaths. More than 10,000 people are expected to ... at diagnosis is 62, it is the one of the most commonly diagnosed cancers in ...
(Date:4/29/2016)... ... April 29, 2016 , ... Reltok Nasal Products proudly announces that Boston ... and neck/ear, nose and throat specialty, has added the KOTLER NASAL AIRWAY™ to its ... is a newly patented safety device secured by nasal surgeons onto the floor ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... ... feature Grassland Dairy Products, Inc. in an upcoming episode, airing third quarter 2016 ... century of churning cream into butter, Grassland Dairy Products, located in Greenwood, Wisconsin ...
Breaking Medicine News(10 mins):